Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant

Seigo Okada, Yoshihiro Azuma, Yasuo Suzuki, Hiroko Yamada, Midori Wakabayashi-Takahara, Yuno Korenaga, Hideaki Akase, Shunji Hasegawa, Shoichi Ohga

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Herein we describe the case of a 6-week-old boy who developed complete Kawasaki disease (KD). The cytokine profile and activation of monocytes and subsequent T cells matched the typical feature of refractory KD. The patient received a total of three courses of i.v. immunoglobulin (IVIG), but did not achieve clinical relief. Adjunctive therapy with oral cyclosporine A (CsA) led to prompt defervescence. This was continued for 7 days without serious adverse events. Coronary artery dilatations regressed within 3 months of follow up. KD infants <3 months of age are at higher risk of coronary artery aneurysm than the older ones. To our knowledge, oral CsA treatment has not been reported in such young infants with KD. The diagnosis and treatment of very young infants with KD are challenging. Adjunctive use of CsA in IVIG treatment could be effective for refractory KD in infants <3 months of age.

Original languageEnglish
Pages (from-to)295-298
Number of pages4
JournalPediatrics International
Volume58
Issue number4
DOIs
Publication statusPublished - Apr 1 2016
Externally publishedYes

Fingerprint

Mucocutaneous Lymph Node Syndrome
Cyclosporine
Immunoglobulins
Coronary Vessels
Therapeutics
Coronary Aneurysm
Dilatation
Monocytes
Cytokines
T-Lymphocytes

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Okada, S., Azuma, Y., Suzuki, Y., Yamada, H., Wakabayashi-Takahara, M., Korenaga, Y., ... Ohga, S. (2016). Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant. Pediatrics International, 58(4), 295-298. https://doi.org/10.1111/ped.12778

Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant. / Okada, Seigo; Azuma, Yoshihiro; Suzuki, Yasuo; Yamada, Hiroko; Wakabayashi-Takahara, Midori; Korenaga, Yuno; Akase, Hideaki; Hasegawa, Shunji; Ohga, Shoichi.

In: Pediatrics International, Vol. 58, No. 4, 01.04.2016, p. 295-298.

Research output: Contribution to journalArticle

Okada, S, Azuma, Y, Suzuki, Y, Yamada, H, Wakabayashi-Takahara, M, Korenaga, Y, Akase, H, Hasegawa, S & Ohga, S 2016, 'Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant', Pediatrics International, vol. 58, no. 4, pp. 295-298. https://doi.org/10.1111/ped.12778
Okada S, Azuma Y, Suzuki Y, Yamada H, Wakabayashi-Takahara M, Korenaga Y et al. Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant. Pediatrics International. 2016 Apr 1;58(4):295-298. https://doi.org/10.1111/ped.12778
Okada, Seigo ; Azuma, Yoshihiro ; Suzuki, Yasuo ; Yamada, Hiroko ; Wakabayashi-Takahara, Midori ; Korenaga, Yuno ; Akase, Hideaki ; Hasegawa, Shunji ; Ohga, Shoichi. / Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant. In: Pediatrics International. 2016 ; Vol. 58, No. 4. pp. 295-298.
@article{d81eba67816d47b284dfe58534f711dc,
title = "Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant",
abstract = "Herein we describe the case of a 6-week-old boy who developed complete Kawasaki disease (KD). The cytokine profile and activation of monocytes and subsequent T cells matched the typical feature of refractory KD. The patient received a total of three courses of i.v. immunoglobulin (IVIG), but did not achieve clinical relief. Adjunctive therapy with oral cyclosporine A (CsA) led to prompt defervescence. This was continued for 7 days without serious adverse events. Coronary artery dilatations regressed within 3 months of follow up. KD infants <3 months of age are at higher risk of coronary artery aneurysm than the older ones. To our knowledge, oral CsA treatment has not been reported in such young infants with KD. The diagnosis and treatment of very young infants with KD are challenging. Adjunctive use of CsA in IVIG treatment could be effective for refractory KD in infants <3 months of age.",
author = "Seigo Okada and Yoshihiro Azuma and Yasuo Suzuki and Hiroko Yamada and Midori Wakabayashi-Takahara and Yuno Korenaga and Hideaki Akase and Shunji Hasegawa and Shoichi Ohga",
year = "2016",
month = "4",
day = "1",
doi = "10.1111/ped.12778",
language = "English",
volume = "58",
pages = "295--298",
journal = "Pediatrics International",
issn = "1328-8067",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Adjunct cyclosporine therapy for refractory Kawasaki disease in a very young infant

AU - Okada, Seigo

AU - Azuma, Yoshihiro

AU - Suzuki, Yasuo

AU - Yamada, Hiroko

AU - Wakabayashi-Takahara, Midori

AU - Korenaga, Yuno

AU - Akase, Hideaki

AU - Hasegawa, Shunji

AU - Ohga, Shoichi

PY - 2016/4/1

Y1 - 2016/4/1

N2 - Herein we describe the case of a 6-week-old boy who developed complete Kawasaki disease (KD). The cytokine profile and activation of monocytes and subsequent T cells matched the typical feature of refractory KD. The patient received a total of three courses of i.v. immunoglobulin (IVIG), but did not achieve clinical relief. Adjunctive therapy with oral cyclosporine A (CsA) led to prompt defervescence. This was continued for 7 days without serious adverse events. Coronary artery dilatations regressed within 3 months of follow up. KD infants <3 months of age are at higher risk of coronary artery aneurysm than the older ones. To our knowledge, oral CsA treatment has not been reported in such young infants with KD. The diagnosis and treatment of very young infants with KD are challenging. Adjunctive use of CsA in IVIG treatment could be effective for refractory KD in infants <3 months of age.

AB - Herein we describe the case of a 6-week-old boy who developed complete Kawasaki disease (KD). The cytokine profile and activation of monocytes and subsequent T cells matched the typical feature of refractory KD. The patient received a total of three courses of i.v. immunoglobulin (IVIG), but did not achieve clinical relief. Adjunctive therapy with oral cyclosporine A (CsA) led to prompt defervescence. This was continued for 7 days without serious adverse events. Coronary artery dilatations regressed within 3 months of follow up. KD infants <3 months of age are at higher risk of coronary artery aneurysm than the older ones. To our knowledge, oral CsA treatment has not been reported in such young infants with KD. The diagnosis and treatment of very young infants with KD are challenging. Adjunctive use of CsA in IVIG treatment could be effective for refractory KD in infants <3 months of age.

UR - http://www.scopus.com/inward/record.url?scp=84949937323&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84949937323&partnerID=8YFLogxK

U2 - 10.1111/ped.12778

DO - 10.1111/ped.12778

M3 - Article

C2 - 26670024

AN - SCOPUS:84949937323

VL - 58

SP - 295

EP - 298

JO - Pediatrics International

JF - Pediatrics International

SN - 1328-8067

IS - 4

ER -